Day: November 16, 2026

Arexera Therapeutics Highlights Potentially Best-in-Class Preclinical Profile and Initiates Clinical Development for ATL-101 in Huntington’s Disease

– ATL-101 achieved robust (~80%) and durable (> 6 months after single administration) HTT lowering in the striatum, the key...

Rejuvenate Biomed Completes Last Patient Visit in Phase 2 Trial of RJx-01 in COPD-Related Muscle Weakness and Advances Regulatory Discussions for Sarcopenia

Last patient has completed the final study visit in the Phase 2 trial in older adults with COPD-induced muscle weakness,...

Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses

FDA IND clearance opens a new era for Oculis in neurology, initiating clinical development in acute MS relapses by building...

Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses

FDA IND clearance opens a new era for Oculis in neurology, initiating clinical development in acute MS relapses by building...

FOR INVESTORS AND FINANCIAL AND BUSINESS MEDIA ONLY Renaissance Pharma secures FDA Breakthrough Therapy Designation for daretabart in newly diagnosed high-risk neuroblastoma

Designation covers daretabart in combination with induction chemotherapy for first-line treatment in paediatric patientsFirst Breakthrough Therapy Designation (BTD) for daretabart,...

Ascentage Pharma Announces Inclusion of Lisaftoclax in China’s 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib

ROCKVILLE, Md., Nov. 15, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated...

Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events – Conference Call Scheduled for 8:30am ET November 16

Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026

error: Content is protected !!